Status:
UNKNOWN
A Registry Study of Biomarkers in Heart Failure
Lead Sponsor:
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Collaborating Sponsors:
Tianjin Medical University Second Hospital
Second Affiliated Hospital of Wenzhou Medical University
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Brief Summary
The registry study aims to discover the prognostic value of bio-markers in heart failure
Detailed Description
The purpose of this study is to investigate the prognostic value of biomarkers in Heart Failure.Patients with confirmed diagnosis of heart failure are enrolled.The primary outcome is all-cause mortali...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 years at the time of admission to the hospital
- With symptoms of new-onset or worsening heart failure
- Received or is eligible to receive a principal hospital discharge diagnosis of HF
- With signs and syndromes as follows: dyspnea at rest or with minimal exertion (dyspnea, orthopnea, or edema)；Rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography.
- Patients who received packed red blood cells, whole blood, or platelets less than 10 days before the blood sample was taken;
Exclusion
- Have objective evidence of cardiac dysfunction documented either by plasma concentrations of BNP and/or N-terminal pro-brain natriuretic peptide (NT-proBNP) \<35 pg/mL or \<125 pg/ml, respectively
- Current known inability to follow instructions or comply with follow-up procedures.
- Eligible patients without informed consent form
Key Trial Info
Start Date :
June 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT03784833
Start Date
June 1 2016
End Date
June 1 2024
Last Update
April 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029